See more : APL Apollo Tubes Limited (APLAPOLLO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Cerus Corporation (CERS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cerus Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Befimmo SA (BEFB.BR) Income Statement Analysis – Financial Results
- Prairie Operating Co. (PROP) Income Statement Analysis – Financial Results
- Euro Multivision Limited (EUROMULTI.NS) Income Statement Analysis – Financial Results
- Dun & Bradstreet Holdings, Inc. (DNB) Income Statement Analysis – Financial Results
- Brookfield Renewable Partners L.P. (BEP-PM.TO) Income Statement Analysis – Financial Results
Cerus Corporation (CERS)
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.37M | 162.05M | 130.86M | 91.92M | 74.65M | 60.91M | 43.57M | 37.18M | 34.22M | 36.50M | 39.66M | 36.70M | 33.04M | 23.11M | 17.98M | 16.51M | 11.04M | 35.58M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 1.85M | 2.40M | 2.90M | 6.90M |
| Cost of Revenue | 69.97M | 74.95M | 63.48M | 41.16M | 33.42M | 31.63M | 22.53M | 20.30M | 23.46M | 21.18M | 22.60M | 20.62M | 18.54M | 12.05M | 12.58M | 9.67M | 5.23M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -634.00K | -600.00K | -700.00K | -700.00K |
| Gross Profit | 86.40M | 87.09M | 67.38M | 50.76M | 41.23M | 29.27M | 21.04M | 16.89M | 10.76M | 15.33M | 17.06M | 16.08M | 14.51M | 11.06M | 5.40M | 6.84M | 5.82M | 34.04M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 2.49M | 3.00M | 3.60M | 7.60M |
| Gross Profit Ratio | 55.25% | 53.75% | 51.49% | 55.23% | 55.23% | 48.06% | 48.29% | 45.42% | 31.44% | 41.99% | 43.01% | 43.82% | 43.91% | 47.87% | 30.04% | 41.43% | 52.66% | 95.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 134.25% | 125.00% | 124.14% | 110.14% |
| Research & Development | 67.64M | 64.11M | 63.69M | 64.41M | 60.38M | 42.56M | 33.71M | 31.32M | 25.64M | 21.69M | 15.19M | 7.60M | 7.18M | 5.20M | 6.37M | 10.21M | 14.96M | 29.51M | 24.13M | 27.65M | 52.48M | 56.42M | 48.25M | 34.82M | 22.50M | 29.80M | 19.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.84M | 52.41M | 48.75M | 45.99M | 37.73M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.52M | 83.34M | 81.29M | 67.02M | 66.21M | 56.84M | 52.41M | 48.75M | 45.99M | 37.79M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Other Expenses | 0.00 | -26.27M | -28.66M | -22.33M | -19.13M | 1.75M | 3.86M | -1.28M | 71.00K | 130.00K | 266.00K | 31.00K | 202.00K | 67.00K | 155.00K | 0.00 | 9.45M | 0.00 | 0.00 | 2.86M | 0.00 | 0.00 | 0.00 | 634.00K | 600.00K | 700.00K | 700.00K |
| Operating Expenses | 115.34M | 121.18M | 116.32M | 109.10M | 107.46M | 84.26M | 78.57M | 78.19M | 71.83M | 59.68M | 45.35M | 33.38M | 30.43M | 26.84M | 28.39M | 37.37M | 48.98M | 43.52M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 42.62M | 27.90M | 34.30M | 23.50M |
| Cost & Expenses | 185.30M | 196.13M | 179.80M | 150.25M | 140.88M | 115.90M | 101.10M | 98.48M | 95.30M | 80.85M | 67.96M | 54.00M | 48.97M | 38.89M | 40.97M | 47.04M | 54.21M | 45.06M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 41.98M | 27.30M | 33.60M | 22.80M |
| Interest Income | 0.00 | 5.83M | 4.92M | 3.75M | 6.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.39M | 5.83M | 4.92M | 3.75M | 6.07M | 4.01M | 3.02M | 2.45M | 1.71M | 599.00K | 520.00K | 551.00K | 964.00K | 689.00K | 302.00K | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.60M | 4.56M | 4.57M | 4.46M | 2.40M | 1.45M | 1.81M | 1.82M | 202.00K | 202.00K | 202.00K | 202.00K | 922.00K | 845.00K | 915.00K | 651.00K | 774.00K | 716.00K | 652.00K | 2.15M | 3.29M | 2.50M | 1.19M | 634.00K | 600.00K | 700.00K | 700.00K |
| EBITDA | -26.54M | -34.08M | -45.99M | -51.37M | -64.61M | -51.88M | -51.87M | -58.47M | -56.14M | -36.55M | -42.04M | -14.38M | -15.10M | -15.38M | -22.92M | -28.53M | -43.17M | -4.06M | -8.69M | -23.01M | -50.54M | -56.78M | -52.69M | -39.51M | -24.29M | -30.00M | -15.20M |
| EBITDA Ratio | -16.97% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -131.58% | -163.91% | -177.66% | -120.94% | -70.85% | -46.59% | -45.40% | -64.61% | -123.18% | -181.01% | -298.28% | -24.63% | -126.29% | -136.45% | -522.96% | -668.79% | -1,161.74% | -2,133.93% | -1,012.50% | -1,075.86% | -237.68% |
| Operating Income | -30.05M | -34.08M | -48.94M | -58.33M | -66.23M | -54.99M | -57.53M | -61.45M | -61.08M | -44.35M | -28.30M | -17.30M | -15.92M | -15.96M | -23.83M | -30.53M | -43.17M | -9.48M | -9.34M | -26.83M | -53.84M | -59.28M | -53.88M | -40.13M | -24.90M | -30.70M | -15.90M |
| Operating Income Ratio | -19.22% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -132.05% | -165.26% | -178.46% | -121.49% | -71.36% | -47.15% | -48.19% | -69.06% | -132.54% | -184.95% | -390.85% | -26.64% | -38.33% | -192.84% | -557.01% | -698.20% | -1,188.05% | -2,168.18% | -1,037.50% | -1,058.62% | -230.43% |
| Total Other Income/Expenses | -7.27M | -8.26M | -5.12M | -1.24M | -4.76M | -2.35M | 832.00K | -1.28M | 1.54M | 5.94M | -14.82M | 1.63M | -1.06M | -953.00K | -302.00K | 1.35M | 4.07M | 4.70M | 22.41M | -4.33M | -4.43M | 2.09M | 4.61M | 4.10M | 0.00 | 1.20M | 1.20M |
| Income Before Tax | -37.32M | -42.34M | -54.06M | -59.57M | -70.98M | -57.34M | -56.70M | -62.73M | -59.54M | -38.37M | -43.12M | -15.68M | -16.98M | -16.91M | -24.67M | 0.00 | -52.62M | -4.78M | 12.75M | -31.15M | -4.43M | -57.19M | -49.27M | -36.03B | 0.00 | -29.50M | -14.70M |
| Income Before Tax Ratio | -23.87% | -26.13% | -41.31% | -64.81% | -95.09% | -94.13% | -130.14% | -168.71% | -173.97% | -105.12% | -108.73% | -42.72% | -51.39% | -73.18% | -137.21% | 0.00% | -476.42% | -13.43% | 52.31% | -223.95% | -45.86% | -673.64% | -1,086.37% | -1,946,682.93% | 0.00% | -1,017.24% | -213.04% |
| Income Tax Expense | 325.00K | 488.00K | 319.00K | 284.00K | 263.00K | 229.00K | 3.89M | 175.00K | -3.67M | 195.00K | 218.00K | 242.00K | 964.00K | 689.00K | 228.00K | -1.35M | 2.14M | 0.00 | -22.41M | 7.19M | 53.84M | 0.00 | 100.00K | 4.10B | -2.30M | -1.10M | -1.20M |
| Net Income | -37.49M | -42.83M | -54.38M | -59.86M | -71.24M | -57.56M | -60.59M | -62.91M | -55.87M | -38.57M | -43.34M | -15.92M | -16.98M | -16.91M | -24.14M | -29.18M | -45.30M | -4.78M | 13.06M | -31.15M | -58.27M | -57.19M | -49.37M | -36.03M | -22.60M | -29.60M | -14.70M |
| Net Income Ratio | -23.98% | -26.43% | -41.55% | -65.12% | -95.44% | -94.51% | -139.06% | -169.18% | -163.25% | -105.65% | -109.28% | -43.38% | -51.39% | -73.18% | -134.22% | -176.78% | -410.21% | -13.43% | 53.60% | -223.95% | -602.87% | -673.64% | -1,088.58% | -1,946.68% | -941.67% | -1,020.69% | -213.04% |
| EPS | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.52 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.18 | 0.58 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| EPS Diluted | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.50 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.17 | 0.55 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| Weighted Avg Shares Out | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 130.83M | 108.19M | 101.46M | 96.07M | 74.77M | 67.57M | 54.52M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 26.87M | 22.35M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
| Weighted Avg Shares Out (Dil) | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 131.66M | 108.22M | 101.83M | 96.91M | 76.53M | 67.57M | 55.06M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 28.61M | 23.95M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2021, provided product revenue guidance for 2022 and provided an update on its INTERCEPT Blood System for Cryoprecipitation offering, which is used to...
4 Growth Stocks Under $10 to Buy for 2022
Growth stocks tend to perform well when the economy starts to pick up. Nissan Motor (NSANY), Arko Corp. (ARKO), Arcos Dorados (ARCO) and Cerus (CERS) look well-poised to grow.
How Much Upside is Left in Cerus (CERS)? Wall Street Analysts Think 44%
The consensus price target hints at a 43.9% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Cerus Corporation to Participate in Stephens Annual Investment Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' chief financial officer, is scheduled to participate in the Stephens Annual Investment Conference in Nashville, Tenn., on Friday, December 3, 2021 at 2:00 p.m. ET. A live...
Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Monday, November...
Cerus Corporation (CERS) CEO Obi Greenman on Q3 2021 Results - Earnings Call Transcript
Cerus Corporation (CERS) CEO Obi Greenman on Q3 2021 Results - Earnings Call Transcript
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2021. Recent developments and highlights include: Third quarter 2021 total revenue of $42.1 million, reflecting a 44% increase over the prior year period....
Cerus Corporation to Release Third Quarter 2021 Financial Results on November 2, 2021
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at...
Source: https://incomestatements.info
Category: Stock Reports